REMSleep Holdings Inc., a medical device company focused on sleep apnea treatment solutions, announced the passing of its founder, Thomas Wood, and the appointment of Jeffrey Marshall as Chief Executive Officer. Wood, who founded the company and served as Chairman and CEO, passed away on February 26, 2026. He was an inventor and entrepreneur who began his design journey in 1981, securing his first U.S. patent for a Nasal Air interface and ultimately being awarded 26 patents for various components of CPAP interfaces. His work led to the formation of REMSleep and the development of the DeltaWave Nasal Pillow System.
Under Wood's leadership, REMSleep achieved significant milestones, including FDA 510(k) clearance for the DeltaWave system and PDAC coding approval enabling Medicare reimbursement. The company also built out its manufacturing and distribution infrastructure, positioning itself for commercial launch. According to the company, Wood had worked over the past several months with his sister, Anita Michaels, the Chief Operating Officer, and incoming CEO Jeffrey Marshall to establish the people, systems, and strategy for a seamless leadership transition.
Following Wood's passing, the Board of Directors has been reconstituted. Anita Michaels, who is Wood's sister, the COO, and the company's majority shareholder, has been elected Chairman of the Board. She began collaborating with her brother in 1981. Jeffrey Marshall has been appointed CEO and Director. Marshall, who has served as a strategy consultant to REMSleep since September 2025, brings extensive industry experience in sales, marketing, and commercial strategy. Alexander Johnson, a strategic advisor to the company, has also been appointed as a Director.
This leadership transition is critical for the medical device industry and for the millions of patients suffering from sleep apnea. The DeltaWave Nasal Pillow System, now commercially available, represents a potential advancement in treatment options. Its successful commercialization could impact patient care standards and create new competition in the sleep therapy market. The company's ability to execute its commercial strategy under new leadership will be a key factor in determining whether this innovative technology reaches its full patient population. For more information on the company, visit https://www.REMSleep.com.
"This transition is a pivotal moment for REMSleep," said Jeffrey Marshall, the newly appointed CEO. "Tom built the foundation achieving FDA clearance, Medicare approval, and a differentiated product. Now it's our job to execute the commercial opportunity he created." Marshall outlined immediate priorities focused on driving sales through strategic marketing plans and building partnerships with Durable Medical Equipment providers, physicians, and sleep labs. The company states this legacy plan, including Board formation and CEO appointment, was in process prior to Wood's passing.
The implications of this announcement extend beyond corporate succession. It tests the resilience of a company built on a founder's vision as it moves into a phase of commercial execution. The success or failure of this transition could influence investor confidence in similar small-cap medical device firms. For the healthcare sector, it highlights the ongoing innovation in treating chronic conditions like sleep apnea and the intricate pathway from patent to FDA clearance to market launch. The company also indicated that Wood's original vision was broader, believing the engineering principles behind DeltaWave could be applied to other chronic respiratory and neurological diseases, a vision now part of the company's strategic roadmap.
